Plain-English translation of NCT05516732 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Researchers are looking for a biological marker—a measurable sign in the brain—that could help detect Parkinson's disease earlier and track how it progresses. This study uses specialized brain imaging scans to examine how serotonin, a brain chemical, changes in people with Parkinson's disease or at genetic risk for it. By finding these markers, doctors hope to improve diagnosis and understand the disease better.
Currently, there's no simple test to diagnose Parkinson's disease in its earliest stages, and it's hard to predict who will develop it. This research aims to fill that gap by identifying measurable brain changes that could lead to earlier detection and better tracking of disease progression.
You likely qualify if…
You likely don't qualify if…
You would attend 5 visits over 3 months at hospitals in London, with each visit lasting about 6 hours. The visits include an initial assessment with blood tests, two different types of brain imaging scans (PET scans), an MRI scan, and a SPECT scan. One optional visit involves a lumbar puncture (spinal tap) to collect fluid. Throughout the study, you'll also complete memory and thinking tests and provide blood and urine samples.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom